Varenicline Prescription and Administration Guidelines for Smoking Cessation

Standard Treatment Duration and Behavioral Support

• The National Comprehensive Cancer Network recommends a standard treatment duration of 12 weeks, with an additional 12-week course for patients who successfully quit smoking to increase the likelihood of long-term abstinence 1
• The National Comprehensive Cancer Network recommends four or more counseling sessions during the 12-week course of pharmacotherapy, with the first session occurring within the first 2-3 weeks of treatment 1
• Counseling sessions should last 10-30+ minutes, with longer and more frequent sessions linked to higher success rates 1

Common Side Effects and Monitoring

• Nausea occurs in 30-40% of varenicline users, typically mild to moderate, and diminishes over time 2
• Monitoring for neuropsychiatric symptoms, including depression and suicidal ideation/behavior, is necessary when using varenicline 2
• Nausea may need careful management, especially in patients with cancer undergoing chemotherapy 1

Follow-up and Relapse Prevention

• Follow-up is recommended within 2-3 weeks after starting pharmacotherapy, with additional periodic follow-up during therapy and after completion 1
• For patients who relapse or fail to achieve abstinence, consider switching to a different pharmacotherapy or intensifying behavioral therapy 3

Varenicline Treatment Regimen

Dosing and Administration

• The National Comprehensive Cancer Network recommends a dosing regimen that begins 1-2 weeks prior to the quit date, with a starter pack containing 53 tablets 4
• The dosing schedule for the starter pack includes 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and 1 mg twice daily for weeks 2-12 4
• The maintenance dose of 1 mg twice daily continues for the remainder of the 12-week treatment period, as recommended by clinical guidelines 4

Treatment Duration and Follow-Up

• The standard treatment duration is 12 weeks, as recommended by clinical guidelines, with an option for an additional 12-week course for patients who successfully quit smoking 4, 5
• Assessment of smoking status and medication side effects should be performed within 2-3 weeks of starting therapy, with additional follow-up recommended at 12 weeks and at the end of therapy 5

Varenicline Dosing and Treatment Strategies

Dosing and Treatment Duration

• Recent research suggests that flexible dosing strategies allowing patients to self-regulate between 0.5 mg/day and 1 mg twice daily may reduce adverse effects while maintaining efficacy 6
• Combining varenicline with behavioral counseling significantly improves outcomes, as recommended by the American Heart Association, with a similar approach suggested by the Mayo Clinic 6, 7

Common Side Effects and Management

• The titration schedule in the starter pack is designed specifically to minimize dose-dependent adverse effects, particularly nausea, with a strategy that may be supported by the Mayo Clinic 6

Smoking Cessation with Varenicline

Efficacy and Comparative Effectiveness

• The National Comprehensive Cancer Network recommends varenicline as the most effective single pharmacotherapy option for smoking cessation, increasing the odds of smoking cessation by almost 3-fold compared with placebo 8, 9
• Varenicline is more efficacious than bupropion and single forms of nicotine replacement therapy, according to the National Comprehensive Cancer Network guidelines 8, 9

Varenicline Treatment Guidelines

Efficacy and Safety

• For patients who successfully quit during the initial 12 weeks, an additional 12-week course of varenicline (total 24 weeks) significantly increases long-term abstinence rates, as validated in a trial of 1,236 smokers, according to the National Comprehensive Cancer Network 10
• Flexible dosing of varenicline (0.5 mg/day to 1 mg twice daily) may reduce adverse effects while maintaining efficacy, allowing patients to self-regulate based on tolerability, with a maximum dose not to exceed 2 mg/day, as doses up to 5 mg/day showed no additional benefit but significantly increased nausea and vomiting, as reported by the National Comprehensive Cancer Network 10, 11

Side Effects and Management

• Nausea occurs in 28-40% of patients, typically peaks in weeks 1-2, and diminishes over time, with the titration schedule addressing this by gradually increasing the dose, and reassurance that nausea typically improves after the first 2 weeks, according to the National Comprehensive Cancer Network 10
• Other common side effects include insomnia (14%) and abnormal dreams (10-13%), as reported by the National Comprehensive Cancer Network 10

Special Considerations

• Monitor for neuropsychiatric symptoms including depression, agitation, behavioral changes, and suicidal ideation throughout treatment, although large-scale trials found no significant increase in neuropsychiatric events with varenicline compared to placebo or nicotine patch, as reported by the National Comprehensive Cancer Network 10, 11
• Patients who previously failed varenicline therapy can be re-treated once factors contributing to the failed attempt are identified and addressed, with varenicline remaining effective and well-tolerated for re-treatment, as demonstrated in an RCT of 498 patients, according to the National Comprehensive Cancer Network 10, 11

Varenicline Treatment Guidelines

Treatment Duration and Efficacy

• The National Comprehensive Cancer Network recommends a standard course of 12 weeks of varenicline treatment, with an option to extend therapy to 6-12 months to promote continued cessation 12
• Varenicline is the most effective single pharmacotherapy for smoking cessation, increasing quit odds almost 3-fold compared to placebo (RR 2.24, 95% CI 2.06-2.43) 12
• Varenicline demonstrates superior efficacy compared to bupropion (RR 1.39, 95% CI 1.25-1.54) and single forms of NRT (RR 1.25, 95% CI 1.14-1.37) 12

Follow-up and Monitoring

• The National Comprehensive Cancer Network recommends follow-up sessions within 2-3 weeks after starting therapy, at 12 weeks, and at the end of therapy if extended beyond 12 weeks 12
• Patients with cancer, especially during chemotherapy, may require careful management of nausea, and varenicline should be avoided in patients with brain metastases due to seizure risk 12

Varenicline Efficacy and Safety for Smoking Cessation

Introduction to Varenicline

• The National Comprehensive Cancer Network recommends varenicline as the most effective single pharmacotherapy for smoking cessation, increasing quit odds almost 3-fold compared to placebo (RR 2.24, 95% CI 2.06-2.43) 13

Efficacy and Safety

• Varenicline demonstrates superior efficacy compared to bupropion (RR 1.39, 95% CI 1.25-1.54) and single forms of nicotine replacement therapy (RR 1.25, 95% CI 1.14-1.37) 13
• Continuous abstinence rates during weeks 9-12 were 43.9% with varenicline versus 29.8% with bupropion and 17.6% with placebo 13
• At 52 weeks, abstinence rates were 23% with varenicline versus 14.6% with bupropion and 10.3% with placebo 13

Special Considerations

• The National Comprehensive Cancer Network considers varenicline to have a favorable risk/benefit ratio, with no significant link between varenicline and increased cardiovascular adverse events 13
• Varenicline is contraindicated in patients with history of serious hypersensitivity or skin reactions to varenicline, and should be avoided in patients with brain metastases or history of seizures due to rare but significant seizure risk 13

Monitoring and Management

• Monitor for neuropsychiatric symptoms including depression, agitation, behavioral changes, and suicidal ideation throughout treatment, although the large EAGLES trial found no significant increase in neuropsychiatric events with varenicline compared to nicotine patch or placebo 13

Smoking Cessation with Varenicline

Introduction to Varenicline Treatment

• The National Comprehensive Cancer Network recommends an extended 24-week approach for successful quitters to maximize long-term abstinence, which includes 12 weeks of initial treatment followed by an additional 12 weeks for patients who successfully quit during the initial period 14
• Varenicline must always be combined with behavioral counseling for optimal outcomes, as recommended by the National Comprehensive Cancer Network 14

Side Effects and Management

• Nausea, which occurs in 28-40% of patients, may require careful management in cancer patients receiving chemotherapy, as noted by the National Comprehensive Cancer Network 14
• Insomnia, experienced by 14% of patients, is another common side effect of varenicline treatment 14

Precautions and Contraindications

• The National Comprehensive Cancer Network advises avoiding varenicline in patients with brain metastases due to an increased seizure risk, and in those with a history of seizures 14

Smoking Cessation with Varenicline

Treatment Regimen

• The National Comprehensive Cancer Network recommends beginning varenicline 1-2 weeks before the quit date, using a titration schedule to minimize nausea, with a target dose of 1 mg twice daily for 12 weeks 15
• For patients who successfully quit during the initial 12 weeks, an additional 12-week course of varenicline (total 24 weeks) is recommended to significantly increase long-term abstinence rates 15

Behavioral Counseling Integration

• The American College of Physicians and other medical societies recommend that varenicline must always be combined with behavioral counseling for optimal outcomes, using a framework such as the 5 A's strategy (Ask, Advise, Assess, Assist, Arrange) 16
• Brief counseling (minimum 3-minute counseling) focusing on motivation and previous quit attempts is recommended, with more intensive counseling (4 or more sessions of 10-30+ minutes) linked to higher success rates 16

Follow-Up Schedule

• The National Comprehensive Cancer Network recommends a first follow-up within 2-3 weeks after starting pharmacotherapy to assess smoking status and medication side effects, with additional follow-up at 12 weeks and at the end of therapy 15
• Minimum follow-up intervals of every 12 weeks during therapy are recommended 15

Monitoring and Safety

• The National Comprehensive Cancer Network recommends monitoring for neuropsychiatric symptoms, including depression, agitation, behavioral changes, and suicidal ideation, throughout treatment with varenicline 15
• Patients with a history of serious hypersensitivity or skin reactions to varenicline should not be treated with this medication 15

Management of Treatment Failure

• The National Comprehensive Cancer Network recommends continuing or resuming initial pharmacotherapy, or switching to combination NRT, before trying other options if a patient fails to quit or relapses 15
• Progressively intensifying behavioral therapy, with referral to specialty care as indicated, is also recommended 15

Restarting Varenicline Therapy for Smoking Cessation

Evidence for Retreatment

• The National Comprehensive Cancer Network (NCCN) guidelines support restarting varenicline in patients who experience relapse or continued smoking after initial therapy, with the option to continue or resume the initial pharmacotherapy, or switch to another primary therapy option before trying subsequent therapy options 17, 18, 19

Clinical Approach to Restarting Varenicline

• Before restarting varenicline, identify and address factors that contributed to the previous treatment failure, including frequent or intense cravings, elevated anxiety, stress, or depression, living or working with smokers, drug or alcohol use/abuse, and inadequate behavioral therapy support 17, 19, 20
• The standard dosing regimen for restarting varenicline includes a titration schedule, starting with 0.5 mg orally once daily for days 1-3, 0.5 mg orally twice daily for days 4-7, and 1 mg orally twice daily for weeks 2-12, if tolerated 18, 20
• A minimum of 12 weeks of treatment is recommended, with therapy potentially extended to 6-12 months to promote continued cessation 18, 20

Intensify Behavioral Support

• As patients progress through multiple lines of treatment, behavior therapy should be progressively intensified with referral to specialty care, as indicated, with a minimum of 4 sessions of individual/group therapy during the 12-week course 17, 19, 20
• Sessions should include skills training, social support, and motivational interviewing 18, 20

Follow-Up Schedule for Retreatment

• Follow-up is recommended within 2-3 weeks after restarting pharmacotherapy, with additional periodic follow-up at minimum 12-week intervals during therapy and after completion, to assess smoking status, medication side effects and tolerability, risk of relapse, and need for dose adjustments or therapy modifications 17, 18, 20

Safety Considerations for Retreatment

• Varenicline is contraindicated in patients with brain metastases due to seizure risk, and caution should be exercised in patients with a history of serious hypersensitivity or skin reactions to varenicline, or conditions that lower seizure threshold 18, 20
• Monitor for development or worsening of serious neuropsychiatric issues, such as depression, suicidal ideation/behavior, agitation, and behavioral changes, throughout treatment 18, 20, 21

Alternative if Varenicline Retreatment Fails

• If the patient fails a second course of varenicline, switch to combination nicotine replacement therapy (NRT) before trying subsequent options, such as combination NRT with bupropion or bupropion alone 17, 19

Long-Term Varenicline Use in Patients with Psychiatric History

Evidence Supporting Safety in Psychiatric Populations

• Varenicline can be safely used long-term (up to 24 weeks) in patients with psychiatric illness, as the large EAGLES trial demonstrated no increased risk of neuropsychiatric adverse events compared to placebo or nicotine patch in over 4,000 patients with diagnosed psychiatric disorders, according to the National Comprehensive Cancer Network 22
• Rates of neuropsychiatric adverse events in individuals receiving varenicline were not significantly increased relative to those receiving nicotine patches or placebo in either cohort of patients with and without diagnosed psychiatric disorders, as reported by the National Comprehensive Cancer Network 22

Common Adverse Events

• Nausea occurs in 28-40% of patients, typically peaks in weeks 1-2 and diminishes over time, and insomnia (14%) and abnormal dreams (10-13%) are also common adverse events, as noted in the Mayo Clinic Proceedings 23

Critical Contraindications and Precautions

• Varenicline is absolutely contraindicated in patients with brain metastases due to seizure risk, as stated by the National Comprehensive Cancer Network 22
• A psychiatric history and suicide risk assessment should be taken before prescription, though current evidence does not support withholding varenicline based solely on psychiatric history, according to the European Heart Journal 24

Comparative Efficacy

• The American College of Cardiology and other guideline societies may recommend varenicline as the most effective single pharmacotherapy for smoking cessation, increasing quit odds almost 3-fold compared to placebo, although this specific recommendation is not cited here, the efficacy of varenicline is supported by the National Comprehensive Cancer Network 22

Initiating and Managing Varenicline for Smoking Cessation

Initiation & Standard Dosing

• Begin varenicline 1–2 weeks before the patient‑chosen quit date and use the NCCN‑recommended titration: 0.5 mg once daily days 1‑3, 0.5 mg twice daily days 4‑7, then 1 mg twice daily from week 2 through week 12. This schedule minimizes nausea while achieving therapeutic levels. 25

Treatment Duration

• A 12‑week course is standard for all patients; extending therapy to a total of 24 weeks for those who achieve abstinence during the first 12 weeks significantly improves long‑term continuous abstinence (≈ 70 % vs ≈ 50 % with placebo at 24 weeks). 25

Contraindications & Precautions

• Absolute contraindications per NCCN: history of brain metastases or an active seizure disorder (due to seizure risk). 25
• Pregnancy and breastfeeding are contraindicated because varenicline is not FDA‑approved for these populations (Annals of Internal Medicine). 26

Mandatory Behavioral Counseling Integration

• Varenicline must be combined with behavioral counseling; pharmacotherapy alone is insufficient (Annals of Internal Medicine). 26
• Minimum counseling requirement: at least four sessions during the 12‑week treatment period, with the first session within 2–3 weeks of starting medication; longer sessions (10–30 minutes or more) are linked to higher quit rates (moderate‑quality evidence). 26
• The 5 A’s framework is recommended; the “Advise” component should deliver a clear, personalized quit recommendation (high‑quality evidence). 26
• At follow‑up visits, clinicians should assess risk of relapse and reinforce counseling support (moderate evidence). 26

Follow‑Up & Monitoring Schedule

• Arrange follow‑up visits (Mayo Clinic Proceedings): first visit 2–3 weeks after initiation (mandatory), second at 12 weeks (end of initial course), and thereafter at minimum every 12 weeks if therapy is extended. 27

Management of Common Side Effects

• Nausea occurs in ~28‑40 % of patients; it usually peaks in weeks 1‑2 and improves thereafter. If intolerable, a flexible dosing approach (e.g., 0.5 mg once daily up to 1 mg twice daily) may be used, allowing patients to self‑adjust based on tolerability (moderate evidence). 27

Neuropsychiatric Safety Monitoring

• The EAGLES trial (≥ 8,000 participants) found no significant increase in neuropsychiatric adverse events with varenicline compared with nicotine patch or placebo, in both patients with and without psychiatric disorders (high‑quality RCT). 25
• Immediate discontinuation is advised if any of the following emerge: worsening depression, suicidal ideation or behavior, agitation, anxiety/panic attacks, or hostility/aggression (NCCN safety guidance). 25

Special Considerations for Oncology Patients

• In patients receiving chemotherapy, varenicline‑related nausea may require especially careful management (NCCN). 25

All bullet points are derived from peer‑reviewed guidelines or high‑quality clinical trials and include the citation identifier for reference.

Varenicline Safety and Efficacy Guidelines

Absolute Contraindications

• Varenicline must be avoided in patients with brain metastases or an active seizure disorder because of a rare but clinically significant seizure risk. National Comprehensive Cancer Network (NCCN) recommends this as an absolute contraindication. 28

Psychiatric Safety

• The EAGLES randomized trial (8,144 participants, including >4,000 with diagnosed psychiatric disorders such as depression, anxiety, bipolar disorder, and schizophrenia) demonstrated that varenicline does not increase neuropsychiatric adverse events compared with placebo or nicotine patch. Evidence level: large, double‑blind RCT. 28
• A 2015 systematic review and meta‑analysis of 39 randomized controlled trials found no increase in suicide attempts, suicidal ideation, depression, or mortality associated with varenicline. Evidence level: high‑quality meta‑analysis. 28
• In adults with stably treated current or past depression, varenicline significantly improved smoking‑cessation rates without worsening anxiety or depressive symptoms. Evidence level: subgroup analysis of RCT data. 28

Cardiovascular Safety

• Recent systematic reviews and meta‑analyses of randomized controlled trials have not identified a statistically significant association between varenicline use and serious cardiovascular adverse events. Evidence level: high‑quality meta‑analysis. 28
• A 2015 retrospective cohort study of 164,766 individuals receiving smoking‑cessation pharmacotherapy showed no elevated risk of cardiovascular events for varenicline compared with nicotine‑replacement therapy. Evidence level: large observational study. 28
• The NCCN panel rates varenicline’s risk/benefit profile as favorable for patients with cardiovascular disease, though clinicians should balance any potential incremental risk against the substantial mortality benefit of quitting smoking. Evidence level: expert consensus. 28
• For patients with recent myocardial infarction or unstable angina, varenicline is not an absolute contraindication; a comprehensive cardiovascular risk assessment is advised, and the mortality benefit of cessation generally outweighs theoretical medication risks. Evidence level: NCCN expert guidance. 28
• Uncontrolled hypertension does not constitute a contraindication, as varenicline does not produce clinically meaningful changes in blood pressure. Evidence level: NCCN guidance. 28

Common Adverse Effects (Non‑Contraindications)

• Nausea occurs in approximately 28 %–40 % of patients, typically peaking during weeks 1–2 and decreasing thereafter; discontinuation due to nausea ranges from 0.6 % to 7.6 %. Evidence level: pooled RCT data. 28
• Insomnia (≈14 %) and abnormal dreams (≈10 %–13 %) are frequently reported but are generally mild in severity. Evidence level: pooled RCT data. 28

Efficacy

• Varenicline increases the odds of quitting smoking by roughly three‑fold compared with placebo (relative risk 2.24; 95 % CI 2.06–2.43) and is more effective than bupropion (RR 1.39) and single‑form nicotine‑replacement therapy (RR 1.25). Evidence level: large meta‑analysis of RCTs. 28
• Continuous abstinence rates at weeks 9–12 range from 43.9 % to 65.4 % with varenicline versus 17.6 % with placebo. Evidence level: RCT outcomes. 28
• At 52 weeks, abstinence is achieved in 23 % of varenicline‑treated patients compared with 10.3 % on placebo. Evidence level: long‑term RCT follow‑up. 28

Clinical Decision Algorithm (Prescription Guidance)

• Screen for absolute contraindications (brain metastases, active seizure disorder, serious hypersensitivity, pregnancy, breastfeeding). If any are present, do not prescribe varenicline; instead use nicotine‑replacement therapy or bupropion. Evidence level: NCCN algorithm (2012). [29][30]

All bullet points are derived from cited evidence and reflect NCCN guideline recommendations where applicable.

Combination Varenicline + Bupropion for Smoking Cessation: Efficacy, Safety, and NCCN Guidance

Efficacy of the Combination

• In adult smokers, adding varenicline to bupropion XL 300 mg yields significantly higher 4‑week continuous abstinence (39.8 % vs 25.9 %) during weeks 8‑11 compared with varenicline alone (OR 1.89, 95 % CI 1.07‑3.35). National Comprehensive Cancer Network (NCCN) guideline recommendation based on a randomized controlled trial (moderate‑quality evidence). 31

• A second randomized controlled trial showed that the combination improves prolonged abstinence at 12 weeks (OR 1.49, 95 % CI 1.05‑2.12) and at 26 weeks (OR 1.52, 95 % CI 1.04‑2.22) versus varenicline monotherapy (moderate‑quality evidence). 31

• NCCN guidelines list varenicline + bupropion as a second‑line pharmacologic option, noting greater efficacy than varenicline alone, particularly in male smokers and those with high nicotine dependence (expert consensus, Level B). 31

Safety and Tolerability

• In the combination‑therapy trial, dose reductions were required in 11.5 % of participants due to adverse effects (clinical trial data). 31

• One randomized trial reported higher rates of anxiety (7.2 % vs 3.1 %) and depressive symptoms (3.6 % vs 0.8 %) with the combination compared with varenicline alone (statistically significant; moderate‑quality evidence). 31

• NCCN advises close neuropsychiatric monitoring when varenicline is added to bupropion, because safety of the combination has not been fully established (expert recommendation). 31

Contraindications and Precautions

• Prior to initiating varenicline, verify the absence of brain metastases or an active seizure disorder (varenicline carries a rare seizure risk; bupropion lowers seizure threshold, overall risk ≈0.1 %). NCCN lists these as absolute contraindications (expert consensus). 31

• Although varenicline does not increase cardiovascular events, smoking cessation can alter the pharmacokinetics of drugs such as warfarin or insulin; therefore, NCCN recommends assessing cardiovascular risk factors before and during therapy (expert recommendation). 31

Dosing and Continuation

• Continue bupropion XL at 300 mg once daily (therapeutic dose) when adding varenicline, as endorsed by NCCN (clinical guideline). 31

Monitoring Recommendations

• NCCN emphasizes heightened vigilance for neuropsychiatric symptoms (depression, suicidal ideation, anxiety, agitation) when varenicline is combined with bupropion, even in patients already stabilized on an SSRI such as escitalopram (expert recommendation). 31

Varenicline for Tobacco Cessation: Evidence‑Based Guidelines

Treatment Duration and Efficacy

• The National Comprehensive Cancer Network (NCCN) recommends extending varenicline therapy to a total of 24 weeks for patients who achieve abstinence during the initial 12‑week course; this extended regimen raises continuous abstinence at 24 weeks from roughly 50 % to 70 % compared with placebo. [Evidence Level: guideline recommendation] 32
• The NCCN notes that varenicline is the most effective single pharmacotherapy for smoking cessation, increasing the odds of quitting by almost three‑fold versus placebo (relative risk 2.24; 95 % CI 2.06–2.43). [Evidence Level: high‑quality meta‑analysis] 33
• Compared with bupropion, varenicline yields a 39 % higher quit rate (RR 1.39; 95 % CI 1.25–1.54); compared with single‑form nicotine replacement therapy, the advantage is 25 % (RR 1.25; 95 % CI 1.14–1.37). [Evidence Level: high‑quality meta‑analysis] 33

Mandatory Behavioral Counseling Integration

• The NCCN requires a minimum of four counseling sessions during the 12‑week varenicline course, with the first session occurring within 2–3 weeks of medication initiation. [Evidence Level: guideline recommendation] 32

Follow‑Up and Monitoring Schedule

• The NCCN advises scheduling the first follow‑up visit 2–3 weeks after starting varenicline to evaluate smoking status and adverse effects, followed by visits at 12 weeks (end of initial treatment) and at the conclusion of any extended therapy. [Evidence Level: guideline recommendation] 32
• At each visit, clinicians should assess smoking status, medication tolerability, and relapse risk factors (e.g., cravings, stress, exposure to other smokers, substance use) and adjust dosing as needed. [Evidence Level: guideline recommendation] 32

Common Side Effects and Management in Oncology Patients

• In patients receiving chemotherapy, nausea is a frequent adverse effect of varenicline; the NCCN highlights the need for careful management in this subgroup. [Evidence Level: guideline recommendation] 32

Neuropsychiatric Safety

• The NCCN states that neuropsychiatric symptoms (depression, agitation, suicidal ideation, etc.) should be monitored throughout treatment, but the large EAGLES trial (≈8,000 participants) demonstrated no significant increase in such events with varenicline versus placebo or nicotine patch. (Trial data cited by NCCN.) [Evidence Level: large randomized trial] 32
• The U.S. Food‑and‑Drug Administration (FDA) removed the black‑box warning for neuropsychiatric adverse events based on this evidence. [Evidence Level: regulatory decision] 34

Absolute Contraindications

• The NCCN lists serious hypersensitivity or skin reactions, active seizure disorder or brain metastases (due to seizure risk), and pregnancy or breastfeeding as absolute contraindications to varenicline. [Evidence Level: guideline recommendation] 32

Management of Treatment Failure or Relapse

• After a failed varenicline attempt, the NCCN recommends reassessing and addressing modifiable factors (insufficient behavioral support, cravings, stress, exposure to other smokers, substance use) before restarting therapy. [Evidence Level: guideline recommendation] 32
• If a second varenicline course is unsuccessful, the NCCN advises switching to combination nicotine‑replacement therapy (patch plus short‑acting form) before considering bupropion. [Evidence Level: guideline recommendation] 32

Combination Therapy Considerations

• High‑quality evidence does not support adding a nicotine patch to varenicline; a 2021 randomized trial of 1,251 smokers showed no difference in 7‑day point‑prevalence abstinence at 52 weeks between varenicline alone (24.8 %) and varenicline + patch (24.3 %). [Evidence Level: randomized controlled trial] 33

All patient‑specific details have been generalized to protect privacy.

Varenicline Use in Patients with Recent Myocardial Infarction and Other High‑Risk Cardiovascular Conditions

Guideline Recommendations for Varenicline

Safety and Efficacy Evidence

Nicotine Replacement Therapy (NRT) Recommendations

Practical Implementation for Post‑MI Patients